GlassScriptPhysician profile
Manisha Sharma
NPI 1720480023
$3,733.46
in general payments reported to CMS, 2019-2025
27 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $768 · 2023: $795 · 2024: $1,112 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.75 | 2023-2025 | |
| Novo Nordisk INC | $345.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $285.11 | 2024-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $283.93 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $241.33 | 2022 | |
| Alk-Abello, INC | $230.11 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.78 | 2022-2024 | Xifaxan, Trulance |
| Amgen INC. | $211.09 | 2022-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $202.81 | 2022-2023 | Spravato |
| Pfizer INC. | $152.87 | 2023-2025 | |
| Exact Sciences Corporation | $146.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $140.95 | 2022-2025 | Trelegy Ellipta, Benlysta, Shingrix |
| Merck Sharp & Dohme LLC | $135.23 | 2022-2023 | Delstrigo, Pifeltro, Dificid |
| Astrazeneca Pharmaceuticals LP | $131.29 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Viiv Healthcare Company | $126.04 | 2025 | Apretude |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $115.64 | 2025 | Uzedy |
| Lilly USA, LLC | $105.04 | 2024 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $64.75 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.26 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $31.49 | 2025 | |
| Organon LLC | $29.35 | 2025 | |
| Theratechnologies INC. | $24.57 | 2023 | Trogarzo, Egrifta |
| Indivior INC. | $20.73 | 2025 | Sublocade |
| Sanofi Pasteur INC. | $19.09 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.37 | 2025 | Nuzyra |
| Neurocrine Biosciences, INC. | $16.18 | 2025 | |
| Redhill Biopharma INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.